Ozempic Vision Loss Lawsuit (NAION): A Separate MDL, Growing Fast
Sudden, usually permanent vision loss in one eye — a different injury from the stomach-paralysis cases, with its own court docket. 200 cases pending as of August 3, 2026, up from 110 two months earlier. No settlement exists.
Editorially Reviewed — Content reviewed for accuracy using published legal research, government data, and verified court records. See our methodology
Reviewed by Leonard Goldberg, Editor · Last updated
What the Lawsuits Allege
Plaintiffs allege that semaglutide — sold as Ozempic, Wegovy and Rybelsus — can cause NAION (non-arteritic anterior ischemic optic neuropathy), and that the manufacturer failed to warn patients and physicians about that risk. NAION is sudden vision loss caused by insufficient blood flow to the optic nerve. It usually affects one eye, and the damage is generally permanent — there is no established treatment that restores the lost vision. Tirzepatide (Mounjaro) is also named in the litigation, though the published research has focused on semaglutide. Novo Nordisk describes NAION as a very rare eye condition and disputes that it is a drug side effect in the legal sense.
Case Details
MDL No. 3163, In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation, U.S. District Court for the Eastern District of Pennsylvania, before Judge Karen S. Marston. Created by JPML transfer order on December 15, 2025. The census dated August 3, 2026 lists 200 pending actions — up from 110 on June 1, so the docket nearly doubled in two months. This is a separate case from MDL 3094, the much larger GLP-1 litigation over gastrointestinal injuries (3,928 pending), which sits before the same judge in the same court. The JPML deliberately split the vision cases out because the injury is different.
Current Status — Verified August 22, 2026
Who May Have a Case
The profile is a patient who took semaglutide (Ozempic, Wegovy or Rybelsus — for diabetes or weight loss) and then experienced sudden vision loss in one eye diagnosed as NAION by an ophthalmologist or neuro-ophthalmologist. Two things decide these cases: the diagnosis itself, which requires an eye specialist's examination and is documented in ophthalmology records, and the timeline — when the medication started relative to when vision was lost. Because NAION also occurs in people who never took these drugs, and shares risk factors with diabetes itself, causation in an individual case is genuinely contested. That is precisely what the September 2026 expert hearings are about.
What This Could Pay (Honest Answer)
Case Timeline
- 1
July 2024: The Harvard-affiliated study
Researchers at Mass Eye and Ear publish in JAMA Ophthalmology a retrospective cohort finding a substantially higher NAION rate among semaglutide patients. The authors themselves flag limitations: small case numbers, a single specialist centre, and a study population that was largely white.
- 2
January 2025: European regulators open a review
The EMA's safety committee begins reviewing semaglutide, noting that two observational studies suggested increased risk while two others did not — the signal was mixed from the start.
- 3
June 2025: NAION classified as a very rare side effect
The EMA's PRAC concludes NAION is a very rare side effect of semaglutide medicines — up to 1 in 10,000 treated patients — and recommends product information be updated: seek immediate medical advice on sudden vision loss, and stop treatment if NAION is confirmed.
- 4
December 15, 2025: The NAION cases get their own MDL
The JPML creates MDL 3163 in the Eastern District of Pennsylvania, separating vision-loss claims from the far larger gastrointestinal GLP-1 litigation.
- 5
August 3, 2026: 200 cases pending
The docket has nearly doubled from 110 on June 1 — one of the faster-growing pharmaceutical MDLs right now.
- 6
September 10–18, 2026: Expert hearings
The court hears challenges to the parties' expert evidence. In pharmaceutical litigation this stage frequently decides whether a case proceeds at all — it is what ended the Tylenol-autism MDL in 2024 before an appeal revived it.
What to Be Careful About
GLP-1 drugs are the most marketed medications in America right now, and the legal advertising around them is equally aggressive.
“Ozempic settlement — claim your payout”
There is no settlement in either GLP-1 MDL, and no claim form. Any site inviting you to claim a payout today is generating leads, not distributing money.
Blurring the two GLP-1 cases
The stomach-paralysis cases (MDL 3094, 3,928 pending) and the vision-loss cases (MDL 3163, 200 pending) are separate dockets over separate injuries. Sites that merge them into one big number are inflating the picture.
“Stop taking your medication to preserve your claim”
Nobody outside your medical team should be advising you about your prescription. Stopping diabetes or weight-management medication has its own serious risks — that decision belongs with your doctor, not with a legal marketer.
Ozempic Vision Loss (NAION) FAQs
Is there an Ozempic vision-loss settlement?
No. MDL 3163 was created in December 2025 and has 200 pending cases as of August 3, 2026. There is no settlement, no administrator and no claim form. Expert hearings are scheduled for September 10–18, 2026.
What exactly is NAION?
Non-arteritic anterior ischemic optic neuropathy: sudden loss of vision caused by insufficient blood flow to the optic nerve, usually in one eye. It typically happens without pain and is generally permanent — there is no established treatment that restores the lost vision.
European regulators called it 'very rare' — does that help or hurt these cases?
Both, in different ways. The EMA's June 2025 conclusion that NAION is a very rare side effect — up to 1 in 10,000 treated patients — is an acknowledgment that the association is real enough to warn about, which plaintiffs point to. But 'very rare' also frames the risk as small, which the defense points to. Regulatory language is not a causation finding in an individual case.
I have diabetes, which also affects eyes. Does that end my case?
No, but it is the central battleground. Diabetes and its vascular effects are independent risk factors for NAION, so the defense will argue the underlying condition explains it. That is exactly why ophthalmology records and the timing of symptom onset relative to starting the medication matter so much.
Is this the same as the Ozempic stomach lawsuits?
No. Those are MDL 3094 — gastroparesis, ileus and related gastrointestinal injuries, with 3,928 cases pending. Vision loss has its own MDL 3163 with 200 cases. Same judge and same court, different dockets, different injuries and different medical evidence.
What about Mounjaro or Zepbound?
Tirzepatide products are named in the litigation, but the published NAION research and the European regulatory action focused on semaglutide. Whether the evidence extends equally to tirzepatide is not settled — an attorney would assess that against your specific medication history.
What records should I gather?
The ophthalmology or neuro-ophthalmology records containing the NAION diagnosis, imaging and visual-field testing, your full prescription history with start dates, and documentation of how the vision loss affects work and daily life. The diagnosis and the dates are the case.
Separate from this case: were you injured in the last 2 years?
Class-action payouts are fixed amounts through an administrator. A personal injury claim is a different case — and often worth far more. Free estimate, no obligation.